Guardant Health

GH · NASDAQ

$162.59+$4.71 (+2.98%)TodayMarket closed · Oct 20, 7:58 PM ET

Prev close $157.88

GH analyst rating

BuyConsensus of 23 analysts over the last 12 months. 96% rate it a buy.

Strong buy0
Buy22
Hold1
Underperform0
Sell0

12-month price target · 30 analysts

Average $200.45 (+23.3% upside)

Low: $108.17
Now: $162.59
High: $236.25

Upgrades and downgrades

The latest rating actions, newest first

GH analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Morgan Stanley	Oct 13, 2026	Maintains	Overweight	$185.00 → $200.00	61%
Barclays	Oct 7, 2026	Maintains	Overweight	$200.00 → $220.00	54%
Guggenheim	Oct 1, 2026	Maintains	Buy	$190.00 → $200.00	66%
UBS	Sep 9, 2026	Maintains	Buy	$175.00 → $225.00	59%
Rothschild & Co	Sep 8, 2026	Initiates	Buy	$203.00	67%
BTIG	Sep 2, 2026	Maintains	Buy	$195.00	54%
Piper Sandler	Aug 4, 2026	Maintains	Overweight	$135.00 → $193.00	58%
Stephens & Co.	Aug 4, 2026	Maintains	Overweight	$170.00 → $195.00	51%
Morgan Stanley	Aug 4, 2026	Maintains	Overweight	$175.00 → $185.00	61%
Stifel	Aug 3, 2026	Maintains	Buy	$130.00 → $180.00	65%

The case for and against

Updated Oct 14, 2026

Bull case

Guardant Health is benefiting from a rare combination of category leadership, reimbursement expansion, and product adoption momentum across liquid biopsy, MRD, and screening. Its flagship Guardant360 franchise has generated strong volume growth, while Reveal is gaining traction from CMS reimbursement and Shield has added major upside from NCCN and ACS guideline inclusion, UNH commercial coverage effective August 1, 2026, and a $1,495 price point. Fundamentally, the business also has substantial operating leverage, with Q1’26 revenue of $302M (+48% Y/Y), gross margin of 65%, $1.2B cash, and multiple catalysts that could lift ASPs and volumes through 2026 and beyond.

Bear case

Guardant Health is facing a fundamental valuation and execution problem because its core Guardant360 franchise still represents more than 60% of sales, making the business highly exposed if growth decelerates from recent 30% Y/Y volumes toward the sub-20% range. Although Shield posted a strong Q1'26 with about $42M of revenue and roughly 44k volumes, the franchise still relies on Medicare-rich pricing of $1,495/test through YE'27, and management expects per-test revenue to fall as commercialization broadens, while cash burn has exceeded $200M in each of the past two years. Meanwhile, downside risk is amplified by uncertainty around the true size of the blood-based screening market, dependence on future USPSTF support, and execution risk around a path to breakeven by Q4 2027.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.